title: Imatinib for the treatment of pulmonary arterial hypertension and pulmonary capillary hemangiomatosis.
abstract: Despite currently available treatments, the prognoses of pulmonary arterial hypertension (PAH) and pulmonary capillary hemangiomatosis (PCH) remain poor. Platelet-derived growth factor and its receptor (PDGFR) have been implicated in the pathogenesis of pulmonary hypertension in PAH and PCH. Imatinib, a PDGFR antagonist, may be beneficial in the treatment of both conditions because of its potent antiproliferative effect. We report two cases that demonstrate the potential for safe and efficacious use of imatinib in PAH and PCH.
authors.affiliation: St. Vincent's Hospital, Sydney, Australia ; University of New South Wales, Kensington, Australia.
authors.forename: Dhruv
authors.initials: D
authors.lastname: Nayyar
authors.affiliation: St. Vincent's Hospital, Sydney, Australia.
authors.forename: Kavitha
authors.initials: K
authors.lastname: Muthiah
authors.affiliation: St. Vincent's Hospital, Sydney, Australia.
authors.forename: Gayathri
authors.initials: G
authors.lastname: Kumarasinghe
authors.affiliation: St. Vincent's Hospital, Sydney, Australia ; University of New South Wales, Kensington, Australia.
authors.forename: Ravin
authors.initials: R
authors.lastname: Hettiarachchi
authors.affiliation: St. Vincent's Hospital, Sydney, Australia.
authors.forename: David
authors.initials: D
authors.lastname: Celermajer
authors.affiliation: St. Vincent's Hospital, Sydney, Australia.
authors.forename: Eugene
authors.initials: E
authors.lastname: Kotlyar
authors.affiliation: St. Vincent's Hospital, Sydney, Australia.
authors.forename: Anne
authors.initials: A
authors.lastname: Keogh